

# Clifford G Tepper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1007547/publications.pdf>

Version: 2024-02-01

53  
papers

3,045  
citations

186265  
28  
h-index

182427  
51  
g-index

56  
all docs

56  
docs citations

56  
times ranked

4698  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of RNA-Seq and a Transgenic Mouse Model to Identify Genes Which May Contribute to Mutant p53-Driven Prostate Cancer Initiation. <i>Biology</i> , 2022, 11, 218.	2.8	1
2	Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients. <i>Journal of Burn Care and Research</i> , 2022, 43, 987-996.	0.4	2
3	KSHV episome tethering sites on host chromosomes and regulation of latency-lytic switch by CHD4. <i>Cell Reports</i> , 2022, 39, 110788.	6.4	23
4	C-terminal tensin-like (CTEN) knockin alleviates cystic kidney defects in Tensin-1 knockout mice. <i>Genes and Diseases</i> , 2022, , .	3.4	1
5	KSHV Topologically Associating Domains in Latent and Reactivated Viral Chromatin. <i>Journal of Virology</i> , 2022, 96, .	3.4	10
6	Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer. <i>Scientific Reports</i> , 2021, 11, 927.	3.3	48
7	Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib. <i>Frontiers in Oncology</i> , 2021, 11, 648097.	2.8	5
8	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. <i>Oncogene</i> , 2021, 40, 5379-5392.	5.9	16
9	KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. <i>Communications Biology</i> , 2021, 4, 1330.	4.4	7
10	Capture Hi-C: Characterization of chromatin contacts. , 2020, , 419-444.		3
11	Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 783-792.	1.4	46
12	KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. <i>Oncogene</i> , 2019, 38, 17-32.	5.9	77
13	Obatoclox, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1285.	4.1	16
14	Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 55.	5.2	32
15	A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 149-162.	2.7	8
16	MicroRNA expression analysis of human skin fibroblasts treated with high-fluence light-emitting diode-red light. <i>Journal of Biophotonics</i> , 2019, 12, e201800207.	2.3	10
17	High frequency of the <i>PNPLA3</i> rs738409 [C] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. <i>Cancer</i> , 2018, 124, 1583-1589.	4.1	16
18	KSHV episomes reveal dynamic chromatin loop formation with domain-specific gene regulation. <i>Nature Communications</i> , 2018, 9, 49.	12.8	36

#	ARTICLE	IF	CITATIONS
19	Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. <i>Nature Communications</i> , 2018, 9, 4700.	12.8	71
20	Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. <i>Theranostics</i> , 2018, 8, 3611-3628.	10.0	58
21	Identification of integrin drug targets for 17 solid tumor types. <i>Oncotarget</i> , 2018, 9, 30146-30162.	1.8	16
22	Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 376-387.	4.1	23
23	Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome. <i>Stem Cell Research and Therapy</i> , 2017, 8, 69.	5.5	42
24	ZIC2 Is Essential for Maintenance of Latency and Is a Target of an Immediate Early Protein during Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation. <i>Journal of Virology</i> , 2017, 91, .	3.4	11
25	Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2627-2638.	4.1	30
26	The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6580-6591.	7.0	43
27	Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. <i>Cancer Letters</i> , 2016, 378, 69-79.	7.2	64
28	Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. <i>Genes and Cancer</i> , 2016, 7, 86-97.	1.9	22
29	Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent. <i>PLoS ONE</i> , 2015, 10, e0129895.	2.5	9
30	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. <i>PLoS ONE</i> , 2015, 10, e0134346.	2.5	72
31	miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. <i>Cancer Research</i> , 2015, 75, 5309-5317.	0.9	63
32	On the Origins of the Androgen Receptor Low Molecular Weight Species. <i>Hormones and Cancer</i> , 2013, 4, 259-269.	4.9	13
33	Biphasic Euchromatin-to-Heterochromatin Transition on the KSHV Genome Following De Novo Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003813.	4.7	88
34	Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. <i>Endocrine-Related Cancer</i> , 2012, 19, 759-777.	3.1	34
35	Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF- $\kappa$ B Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop. <i>Molecular and Cellular Biology</i> , 2012, 32, 3121-3131.	2.3	123
36	Modeling Truncated AR Expression in a Natural Androgen Responsive Environment and Identification of RHOB as a Direct Transcriptional Target. <i>PLoS ONE</i> , 2012, 7, e49887.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 185-194.	2.3	18
38	Dual Blockade of PKA and NF- $\kappa$ B Inhibits H2 Relaxin-Mediated Castrate-Resistant Growth of Prostate Cancer Sublines and Induces Apoptosis. <i>Hormones and Cancer</i> , 2011, 2, 224-238.	4.9	32
39	Histone Demethylase JMJD2A Regulates Kaposi's Sarcoma-Associated Herpesvirus Replication and Is Targeted by a Viral Transcriptional Factor. <i>Journal of Virology</i> , 2011, 85, 3283-3293.	3.4	52
40	Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. <i>Endocrine-Related Cancer</i> , 2010, 17, 857-873.	3.1	32
41	KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9671-9676.	7.1	164
42	Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells. <i>Cancer Research</i> , 2010, 70, 5994-6003.	0.9	49
43	Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 3339-3346.	0.9	133
44	A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth. <i>Cancer Research</i> , 2009, 69, 2305-2313.	0.9	763
45	Cellular and Molecular Signatures of Androgen Ablation of Prostate Cancer. , 2009, , 507-551.		1
46	Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer. <i>Cancer Research</i> , 2008, 68, 2250-2258.	0.9	81
47	Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence. <i>Cancer Research</i> , 2007, 67, 9001-9005.	0.9	120
48	GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. <i>Prostate</i> , 2007, 67, 521-535.	2.3	37
49	ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. <i>Prostate</i> , 2006, 66, 1474-1486.	2.3	45
50	Inappropriate Activation of the Androgen Receptor by Nonsteroids: Involvement of the Src Kinase Pathway and Its Therapeutic Implications. <i>Cancer Research</i> , 2006, 66, 10449-10459.	0.9	56
51	Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. <i>Prostate</i> , 2005, 65, 375-389.	2.3	30
52	Molecular alterations associated with LNCaP cell progression to androgen independence. <i>Prostate</i> , 2004, 60, 257-271.	2.3	73
53	Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. <i>Cancer Research</i> , 2002, 62, 6606-14.	0.9	206